Enliven Therapeutics (ELVN) investor relations material

Clinical development and product differentiation

• ELVN-001 aims to outperform SCEMBLIX by offering superior efficacy in deep molecular response and better tolerability, especially in cytopenias and cardiovascular toxicity, with added convenience factors like a better DDI profile and no food effect.

• The opportunity is split roughly half between newly diagnosed and previously treated CML patients, with the drug expected to be comparably successful in both settings.

• Key clinical endpoints include major molecular response (MMR), deep molecular response, and discontinuation rates due to adverse events, which influence prescribing behavior.

• The largest commercial share is expected from improvements over first, second, and third generation TKIs, with switching driven by both efficacy and tolerability.

• ENABLE-2 phase III trial design is well aligned with regulatory expectations, with execution being the main focus for timely progress.

Market opportunity and strategic outlook

• The U.S. CML market is estimated at $10 billion, with a global opportunity of $16 billion, driven by both price and growing patient population.

• The company holds $895 million in cash, providing runway into 2030 and supporting pivotal trial milestones for both CML and Graves' disease programs.

• Near-term catalysts include phase III study initiation, phase I data updates, and new trials in combination therapies and frontline CML, with Graves' disease IND clearance targeted for early next year.

• AI is being leveraged to accelerate clinical and regulatory processes, mainly improving efficiency and timelines.

• The company is focused on known biology and validated targets, with future pipeline expansion likely through business development, especially considering innovation from China.

Long-term vision and regulatory focus

• The company may evolve into a multi-asset, multi-therapeutic area organization, with flexibility to monetize or expand its pipeline based on strategic choices.

• Regulatory focus is on FDA, EMA, and global health authorities, with attention to pricing and launch sequencing as approval nears.

• The Graves' disease program is positioned as a potential best-in-class, once-daily oral therapy addressing significant unmet need.

• The company’s approach is to maintain a de-risked, high-probability phase III asset in a large market, aiming for transformative impact.